Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Circulation Research

• Publication date

  2016-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCRESAHA.116.306924PMID 27230644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAMA Cardiology.

  2018cited by this paper
• Outpatient Worsening Heart Failure as a Target for Therapy: A Review

  2018cited by this paper
• Will long‐acting glucagon‐like peptide‐1 analogues recapitulate our agonizing experience with cyclic AMP‐dependent positive inotropic agents in heart failure?

  2018cited by this paper
• Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

  2018cited by this paper
• Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium

  2017cited by this paper
• Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association

  2017cited by this paper
• Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial

  2017cited by this paper
• Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.

  2017cited by this paper
• The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?

  2017cited by this paper
• Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits.

  2017cited by this paper
• Novel Diabetes Drugs and the Cardiovascular Specialist.

  2017cited by this paper
• Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.

  2017cited by this paper
• The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors

  2017cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

  2016cited by this paper
• Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

  2016cited by this paper
• Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).

  2016cited by this paper
• Heart failure event definitions in drug trials in patients with type 2 diabetes.

  2016cited by this paper
• Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

  2016cited by this paper
• Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015influential reference
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Proceedings of the Australian Physiological Society Symposium: Molecular Control of Skeletal Muscle Health in Exercise and Disease Metabolic remodelling in obesity and type 2 diabetes: pathological or protective mechanisms in response to nutrient excess?

  2015cited by this paper
• Chronic Hyperinsulinemia Causes Selective Insulin Resistance and Down-regulates Uncoupling Protein 3 (UCP3) through the Activation of Sterol Regulatory Element-binding Protein (SREBP)-1 Transcription Factor in the Mouse Heart*

  2015cited by this paper
• 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications

  2015influential reference
• Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes

  2015cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

  2015cited by this paper
• Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry

  2015cited by this paper
• Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

  2015cited by this paper
• Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

  2015cited by this paper
• Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

  2015influential reference
• The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

  2015influential reference
• Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.

  2015cited by this paper
• Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005–2011

  2015cited by this paper
• DPP-4 inhibitors and risk of heart failure EXAMINEd.

  2015cited by this paper
• Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.

  2015cited by this paper
• Remodeling of Glucose Metabolism Precedes Pressure Overload-Induced Left Ventricular Hypertrophy: Review of a Hypothesis

  2015cited by this paper
• Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

  2015cited by this paper
• A Randomized Trial of Liraglutide for High-Risk Heart Failure Patients With Reduced Ejection Fraction

  2015cited by this paper
• 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).

  2015cited by this paper
• Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls

  2014cited by this paper
• Recognizing worsening chronic heart failure as an entity and an end point in clinical trials.

  2014cited by this paper
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014influential reference
• Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.

  2014cited by this paper
• The imperative of overcoming barriers to the conduct of large, simple trials.

  2014cited by this paper
• Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

  2014cited by this paper
• Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

  2014cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

  2014cited by this paper
• Management of comorbid diabetes mellitus and worsening heart failure.

  2014cited by this paper
• Matrix Revisited: Mechanisms Linking Energy Substrate Metabolism to the Function of the Heart

  2014cited by this paper
• On the potential of acarbose to reduce cardiovascular disease

  2014influential reference
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

  2014influential reference
• Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial

  2014cited by this paper
• Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT‐CRT

  2014cited by this paper
• SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together.

  2013cited by this paper
• Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients

  2013influential reference
• A Role for Peroxisome Proliferator-activated Receptor γ Coactivator 1 (PGC-1) in the Regulation of Cardiac Mitochondrial Phospholipid Biosynthesis*♦

  2013cited by this paper
• Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.

  2013cited by this paper
• Insulin resistance protects the heart from fuel overload in dysregulated metabolic states.

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

  2013cited by this paper
• SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory

  2013cited by this paper
• Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial

  2013cited by this paper
• Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Results of a reevaluation of cardiovascular outcomes in the RECORD trial.

  2013cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry

  2012influential reference
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 = Akut ve Kronik Kalp Yetersizligi Tani ve Tedavisine Yönelik 2012 ESC Kilavuzu

  2012cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Cardiovascular biology of the incretin system.

  2012cited by this paper
• Insulin Resistance, Obesity, Hypertension, and Renal Sodium Transport

  2011cited by this paper
• Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus

  2011cited by this paper
• Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets.

  2010cited by this paper
• The clinical significance of hyperfiltration in diabetes

  2010cited by this paper
• Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure

  2010influential reference
• Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.

  2010cited by this paper
• Epithelial Na+ Channel (ENaC), Hormones, and Hypertension*

  2010cited by this paper
• ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES

  2010cited by this paper
• A randomized trial of therapies for type 2 diabetes and coronary artery disease.

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Intensive glucose control and macrovascular outcomes in type 2 diabetes

  2009cited by this paper
• Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus

  2009cited by this paper
• Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

  2009cited by this paper
• Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

  2009cited by this paper

• Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy

  2025cites this paper
• Sitagliptin, diabetes mellitus, and heart failure: an in-depth review of sitagliptin therapy and heart failure in patients with diabetes mellitus

  2025cites this paper
• Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study

  2025cites this paper
• The human genetic variant rs6190 unveils Foxc1 and Arid5a as novel prometabolic targets of the glucocorticoid receptor in muscle

  2025cites this paper
• The human genetic variant rs6190 unveils Foxc1 and Arid5a as novel pro-metabolic targets of the glucocorticoid receptor in muscle

  2024cites this paper
• Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies

  2022cites this paper
• Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension

  2022cites this paper
• Antidiabetic agents: Do they hit the right targets?

  2022cites this paper
• Type 2 diabetes mellitus and chronic heart failure: new treatment strategies

  2021influential citation
• Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes

  2021cites this paper
• The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review

  2021cites this paper
• A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

  2021cites this paper
• Heart failure at the crossroads of cardiology and diabetology.

  2021cites this paper
• Treatment Effect of Type 2 Diabetes Patients in Outpatient Department Based on Blockchain Electronic Mobile Medical App

  2021cites this paper
• Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

  2021cites this paper
• Risk-Based Approach for the Prediction and Prevention of Heart Failure.

  2021cites this paper
• Myocardial Extracellular Volume Fraction and T1 Mapping by Cardiac Magnetic Resonance Compared Between Patients With and Without Type 2 Diabetes, and the Effect of ECV and T2D on Cardiovascular Outcomes

  2021cites this paper
• Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

  2021cites this paper
• TYPE 2 DIABETES MELLITUS’S DECOMPENSATED FORM: ON THE PROBLEM OF EFFECTIVE PHARMACOTHERAPY IN REAL CLINICAL PRACTICE

  2021cites this paper
• Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

  2020cites this paper
• Treatment Paradigm Shifting Implications of Recent Cardiovascular Outcome Trials: Core Insights on the Brink of the 2020ies.

  2020cites this paper
• Importance de l’évaluation du risque cardiovasculaire pour une préconisation personnalisée des nouveaux traitements anti-hyperglycémiants en prévention cardiovasculaire

  2020cites this paper
• Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease

  2020cites this paper
• Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy

  2020cites this paper
• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

  2020cites this paper
• Insulin: too much of a good thing is bad

  2020cites this paper
• Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.

  2019cites this paper
• Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease.

  2019cites this paper
• Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.

  2019cites this paper
• Congestive heart failure caused by silent ischemia and silent myocardial infarction

  2019cites this paper
• Myocardial GLP-1 Receptor Activation in the Presence of Glucose: Strong Partners

  2019cites this paper
• Exploration of artistic creation of Chinese ink style painting based on deep learning framework and convolutional neural network model

  2019cites this paper
• The Effectiveness of Acceptance and Commitment Therapy (ACT) on Psychological Symptoms and Life Satisfaction in Patients with Type-2 Diabetes

  2019cites this paper
• Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score

  2019cites this paper
• CVOTs: What did the Endocrinologist learn ?

  2019cites this paper
• Regulating Inflammatory Cytokines in the Diabetic Heart

  2019cites this paper
• A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus

  2019cites this paper
• Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL

  2019cites this paper
• 2020 vision - An overview of prospects for diabetes management and prevention in the next decade.

  2018cites this paper
• A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity

  2018cites this paper
• Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure.

  2018cites this paper
• Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

  2018cites this paper
• Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.

  2018cites this paper
• SFRP5 is a target gene transcriptionally regulated by PPARγ in 3T3-L1 adipocytes.

  2018cites this paper
• Heart failure in diabetes: From an increased risk to a treatment target

  2018cites this paper
• Pharmacotherapy of type 2 diabetes: An update.

  2018cites this paper
• Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

  2017cites this paper
• Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes

  2017cites this paper
• GLP-1 receptor agonists and heart failure in diabetes.

  2017cites this paper
• The effect of acceptance and commitment therapy on the mental health of women patients with type II diabetes

  2017cites this paper
• Vignette therapeutique de l'etudiant. Quel medicament antidiabetique choisir chez un patient diabetique de type 2 avec insuffisance cardiaque ?

  2017cites this paper
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.

  2017cites this paper
• Apigenin alleviates STZ-induced diabetic cardiomyopathy

  2017cites this paper
• Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group

  2017cites this paper
• The pathophysiological basis of the protective effects of metformin in heart failure.

  2017cites this paper
• Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.

  2017cites this paper
• Obesity, Diabetes, and Cardiovascular Diseases: A Compendium.

  2016cites this paper
• Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum.

  2016cites this paper
• Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

  2016cites this paper
• SGLT2 Inhibitors: Benefit/Risk Balance

  2016cites this paper
• The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart

  2016cites this paper
• Herzinsuffizienz und Diabetes – therapeutische Möglichkeiten

  2016cites this paper